Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Healthy
Interventions
PMI-150 (intranasal ketamine HCl); mometasone furoate
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Ketamine for Depression: An MRI Study

NCT02544607
Conditions
Depression, Anxious Depression, Major Depressive Disorder
Interventions
Ketamine, Magnetic Resonance Imaging (MRI)
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Pain Management, Analgesic, Nonopioid, Amputation of Lower Extremity, All Causes
Interventions
Oral Ketamine
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine infusion, Saline
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Complex Regional Pain Syndromes
Interventions
80mg/day Ketamine HCl Prolonged Release, 160mg/day Ketamine HCl Prolonged Release
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 64 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Completed Not applicable Interventional Results available

Pharmacokinetics of Ketamine in Infants and Children

NCT00553839
Conditions
The Pk of IV Ketamine in Children With Heart Disease
Interventions
ketamine hydrochloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Palo Alto, California • Denver, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers

Ketamine Infusions for PTSD and Treatment-Resistant Depression

NCT02577250
Conditions
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Interventions
Ketamine
Drug
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Traumatic Brain Injury, Traumatic Encephalopathy
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Obsessive-Compulsive Disorder
Interventions
Intranasal Ketamine, Intranasal Midazolam
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

NCT04589208
Conditions
Healthy
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Major Depressive Disorder, Healthy Controls
Interventions
Ketamine Hydrochloride, Midazolam injection
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Psychiatric Disorder
Interventions
Ketamine Hydrochloride
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Palo Alto, California
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Conditions
Anorexia Nervosa
Interventions
Ketamine Hcl 50Mg/Ml Inj
Drug
Lead sponsor
Homeostasis Therapeutics, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
South Windsor, Connecticut
Conditions
Postoperative Pain Control, Opioid Consumption
Interventions
Ketamine, Placebo Ketamine, Lidocaine, Placebo Lidocaine, Acetaminophen, Placebo Acetaminophen, Gabapentin, Placebo Gabapentin, Celecoxib, Placebo Celecoxib
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Traumatic Injury
Interventions
Ketamine Hydrochloride, Fentanyl Citrate
Drug
Lead sponsor
Jason Sperry
Other
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Camden, New Jersey + 7 more
Conditions
Neurotoxicity, Pain, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ketamine/amitriptyline NP-H cream, placebo
Drug · Other
Lead sponsor
Gary Morrow
Other
Eligibility
18 Years to 120 Years
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
17
States / cities
Honolulu, Hawaii • Chicago, Illinois • Decatur, Illinois + 14 more
Completed Phase 2 Interventional Accepts healthy volunteers

Understanding How Ketamine Brings About Rapid Improvement in OCD

NCT02624596
Conditions
Obsessive-Compulsive Disorder
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Stanford, California
Conditions
Postoperative Quality of Recovery
Interventions
Opioid Free Total Intravenous Anesthesia, Total Intravenous anesthesia with opioid
Combination Product
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Manhasset, New York
Conditions
Neuropathic Pain, PTSD
Interventions
Ketamine, Magnesium sulfate, Ketamine + Magnesium sulfate
Drug
Lead sponsor
Margaux M. Salas, PhD
Federal
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Depression
Interventions
Ketamine Hydrochloride, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Major Depressive Disorder
Interventions
Esketamine, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • San Diego, California • Hartford, Connecticut + 11 more
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Conditions
Acute Traumatic Pain
Interventions
Ketamine Hydrochloride, Placebo-Comparator
Drug
Lead sponsor
Jason McMullan
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio